An international research group has reported promising data from an early clinical trial of a prophylactic vaccine against HIV-1 in healthy volunteers and a parallel study of the same vaccine in rhesus monkeys. The study results were published online in The Lancet on 6 July.
Forbion Capital Partners of the Netherlands has raised €270 million at the first close of its fourth life science fund, exceeding the target amount of €250 million. Forbion IV will support promising biotech companies predominately in the UK and the EU.
About 20% of the funds will target opportunities in North America.
The Wellcome Trust is to use its expertise in life science and financial muscle to launch a new investment fund that will enable high-risk research projects to develop quickly and move towards commercialisation. The Wellcome Leap Fund will have capital of £250 million to be allocated over five years starting in 2020.
The fund will be wholly owned by the Trust with its own chief executive officer and an independent board of directors. Recruitment of the CEO is expected to start shortly, the Trust announced on 10 July.
London, UK-based Abingworth has raised $315 million for its twelfth life science fund bringing the total amount of funds under management to over $1.2 billion. The new fund, Abingworth Bioventures VII, will invest in companies in Europe and the US.
Abingworth invests across all stages of drug development including early and late-stage venture deals, clinical co-development projects and public equities. The typical investment per company is in the range of $15 to $30 million.
A prospective drug for Alzheimer’s disease that failed to show efficacy in late 2017 based on a Bayesian analysis of patient data, has now demonstrated its promise using more conventional statistical methods, according to Eisai Co Ltd and Biogen Inc.
The drug, BAN2401, is a monoclonal antibody targeting beta-amyloid, protein fragments in the brain which are thought to contribute to the neurodegenerative process in Alzheimer’s disease.
A consortium of predominately European investors is providing €47 million to Dynacure SAS of France to bring its candidate antisense oligonucleotide drug into the clinic for the treatment of patients with centronuclear myopathies.
Centronuclear myopathies are genetic disorders characterised by muscle weakness and wasting in the skeletal muscles. Dynacure’s lead product, Dyn101, is intended to treat these disorders by targeting dynamin 2, a protein that is implicated in cell processes such and cell motility and endocytosis.
Ipsen SA received further validation of its in-licensed compound cabozantinib following the publication in the 5 July edition of the New England Journal of Medicine (NEJM) of Phase 3 data showing the drug’s effectiveness in advanced liver cancer. Cabozantinib, which trades commercially as Cabometyx, has already been approved in the US and Europe for advanced kidney cancer. The drug was developed by Exelixis Inc and out-licensed to Ipsen in 2016 for commercialisation outside the US, Canada and Japan. Ipsen later acquired rights to Canada.
Deborah Dunsire, an experienced pharmaceutical company chief executive, is set to become CEO of H. Lundbeck A/S on 1 September. Trained as a medical doctor, Dr Dunsire has managed both biotech and pharmaceutical companies in the fields of oncology and central nervous system disorders. Her most recent position is as CEO of the oncology company XTuit Pharmaceuticals Inc. She has also been CEO of FORUM Pharmaceuticals Inc and of Millennium Pharmaceuticals Inc, now part of Takeda Pharmaceutical Co Ltd.
A candidate vaccine to prevent infection from the chikungunya virus has been accepted into the European Medicines Agency’s PRIME scheme, a programme of regulatory support for developers of medicines that meet a major public health need.
The vaccine is a biologic developed by Themis Bioscience GmbH of Austria and is currently undergoing Phase 2 studies in 600 patients across the US, the EU and South and Central America. The company hopes to receive marketing approval within three years.
Valneva SE is poised to bring its prophylactic vaccine for Lyme disease into a Phase 2 clinical study by the end of 2018 following positive discussions with the US Food and Drug Administration, the company announced on 2 July. The agency has given the product ‘fast track’ status in light of its potential contribution to public health.